杰华生物技术

Genneva Biopharmaceutical is a biotechnology company specializing in the development of novel protein-based therapeutics for viral diseases and oncology. The company's flagship product, Novaferon (乐复能), is a first-in-class recombinant protein that has been approved by the NMPA in China for the treatment of chronic hepatitis B. Genneva leverages its proprietary protein engineering platform to design biologics with improved therapeutic indices compared to conventional interferon treatments. Headquartered in Qingdao, China, the company operates large-scale GMP manufacturing facilities and maintains a research presence focused on expanding Novaferon's indications to include various solid tumors. Genneva aims to address significant unmet medical needs in the global healthcare market through innovative immunotherapy solutions. The company is recognized as a leader in the Chinese biologics sector for its successful commercialization of a Category 1 innovative drug.